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Abstract
Purpose To investigate which clinical factors and laboratory values are associated with high FDG uptake in the bonemarrow and
spleen on 2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomography (PET)/computed tomography (CT) in patients
with bacteremia.
Methods One hundred forty-five consecutive retrospective patients with bacteremia who underwent FDG-PET/CT between
2010 and 2017 were included. Mean standard uptake values (SUVmean) of FDG in bone marrow, liver, and spleen were
measured. Bone marrow-to-liver SUV ratios (BLR) and spleen-to-liver SUV ratios (SLR) were calculated. Linear regression
analyses were performed to examine the association of BLR and SLR with age, gender, hemoglobin, leukocyte count, platelets,
glucose level, C-reactive protein (CRP), microorganism, days of antibiotic treatment before FDG-PET/CT, infection focus, use of
immunosuppressive drugs, duration of hospital stay (after FDG-PET/CT), ICU admission, and mortality.
Results C-reactive protein (p = 0.006), a cardiovascular or musculoskeletal focus of infection (p = 0.000 for both), and bacter-
emia caused by Gram-negative bacteria (p = 0.002) were independently and positively associated with BLR, while age (p =
0.000) and glucose level before FDG-PET/CT (p = 0.004) were independently and negatively associated with BLR.
For SLR, CRP (p = 0.001) and a cardiovascular focus of infection (p = 0.020) were independently and positively associated
with SLR, while age (p = 0.002) and glucose level before FDG-PET/CT (p = 0.016) were independently and negatively associ-
ated with SLR.
Conclusion High FDG uptake in the bone marrow is associated with a higher inflammatory response and younger age in patients
with bacteremia. In patients with high FDG uptake in the bone marrow, a cardiovascular or musculoskeletal focus of infection is
more likely than other foci, and the infection is more often caused by Gram-negative species. High splenic FDG uptake is
associated with a higher inflammatory response as well, and a cardiovascular focus of infection is also more likely in case of high
splenic FDG uptake.
Keywords Bacteremia . Bonemarrow . Spleen . FDG . Uptake . Sepsis
Introduction
Infection is one of the most common reasons for hospital
admission [1]. In patients with systemic signs of infection
such as fever, blood cultures may be obtained to assess wheth-
er bacteria crossed anatomic barriers of the body and entered
the bloodstream, causing bacteremia [2, 3]. With a 30-day
mortality rate higher than 15%, bacteremia ranks among the
top 10 causes of death in Europe and North America [4, 5].
2-Deoxy-2-[18F]fluoro-D-glucose (FDG) PET/CT can be
used to evaluate the whole body for a focus of bacteremia in
one examination. As white blood cells and other inflammatory
cells are drawn to sites of infection and consume more
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glucose, infection sites are often readily visible on FDG-PET/
CT, even before anatomical changes (such as abscess forma-
tion) have occurred [6]. In the last two decades, FDG-PET/CT
has established its role in a broad spectrum of infectious dis-
eases, including bacteremia (of unknown origin) [6, 7].
In some patients undergoing FDG-PET/CT for detecting
the focus of infection, markedly increased FDG uptake is seen
in the bone marrow or spleen. The bone marrow and spleen
are generally regarded as “hypermetabolic” when their FDG
avidity exceeds that of the liver (bone marrow/liver ratio or
spleen/liver ratio > 1.0) [8]. Hypermetabolism of the bone
marrow or spleen has been associated with laboratory values
such as C-reactive protein or hemoglobin and even prognosis
in patients with several types of cancer [9–14] and autoim-
mune disease [15, 16]. However, the clinical and pathophys-
iological meaning of hypermetabolism of the bone marrow
and spleen in patients with bacteremia is limited. In a study
by Ahn et al., FDG uptake in the spleen seemed a useful
measure to discriminate between autoimmune disease and
bacteremia [16]. And, in a study by Boursier et al., high
FDG uptake of the bone marrow and spleen was independent-
ly associated with endocarditis [17].
In current clinical practice, high FDG uptake of the bone
marrow or spleen is generally not taken into account in pa-
tients with bacteremia undergoing FDG-PET/CT for finding
the focus of infection because the implications of this finding
remain largely unknown in this patient category.
In this study, we investigated the pathophysiological and
clinical implications of high FDG uptake in the bone marrow
and spleen on FDG-PET/CT in a large number of patients
with bacteremia.
Materials and methods
Study design and patients
The electronic patient database of the University Medical
Center Groningen was searched for all patients with bacter-
emia who underwent FDG-PET/CT for finding the focus of
infection between 2010 and 2017 using the keywords “sep-
sis,” “bacteremia,” “infection focus,” and “blood culture.”
Patients were included if they had positive blood cultures
within 2 months before FDG-PET/CT was performed.
Patients were excluded if they had positive blood cultures that
were interpreted as contamination by the medical microbiolo-
gist, if FDG-PET images were not available for quantitative
measurements, if patients had malignant disease such as leu-
kemia or lymphoma (as these patients may have abnormal
FDG uptake in the bonemarrow or spleen due to their cancer),
and if they had glucose levels above 11 mmol/L (198 mg/dL)
before FDG administration. Follow-up FDG-PET/CT scans
and FDG-PET/CT scans performed for other reasons than
locating the source of infection (such as oncologic follow-
up) were excluded as well.
The Medical Ethics Review Board of the University
Medical Center Groningen approved this retrospective,
single-center study and waived the requirement for written
informed consent (Institutional Review Board number
201700145). The patient cohort analyzed in this study is pre-
viously described [18].
Patient data review
The medical files of all patients were reviewed for relevant
clinical and biochemical data including age, gender, medical
history, laboratory values (hemoglobin, platelets, CRP, leuko-
cyte count, glucose level, type of bacteria), imaging results
and procedures, admission to intensive care unit, medication
and treatment, and follow-up data. The final diagnosis was
based on all available clinical data and diagnostic test results
including histology and microbiology reports, FDG-PET/CT
results and other types of imaging that were performed, clin-
ical response to treatment, and follow-up for at least 6 months.
FDG-PET/CT acquisition
All scans were performed using an integrated PET/CT system
(Biograph mCT 40 or 64 slice PET/CT; Siemens, Knoxville,
TN, USA) with 3 min per bed position according to European
Association of Nuclear Medicine guidelines [19]. Patients
fasted for a minimum of 6 h before 3 MBq FDG/kg body
weight was administered intravenously. When there was a
clinical suspicion of infective endocarditis, patients were also
prepared with a high-fat, low-carbohydrate diet for at least
24 h. PET/CT imaging was performed approximately
60 min after intravenous FDG administration.
Low-dose CT was performed for attenuation correction
and anatomic mapping with 100 kV and 30 mAs. In 28 pa-
tients, concomitant full-dose CT of neck, thorax, or abdomen
was performed with a constant tube potential of 100 or 120 kV
and automatic adjustment of mAs in the z-direction.
Quantitative FDG-PET measurements
In all included patients, mean standardized FDGuptake values
(SUVmean) were determined using Syngovia software
(Siemens Healthcare, Erlangen, Germany). Bone marrow
SUVmean values were measured with spherical volumes of
interest (VOI) at four anatomical landmarks (the right femur
head, the corpus of the first thoracic and first lumbar vertebrae,
and the right posterior iliac crest) and then averaged. The
right-sided femur head and posterior iliac crest were chosen
as most patients were presumed to be right limb dominant.
The VOI diameters were set in the bone marrow, excluding
cortical bone and entities on CT such as Schmorl’s nodes in
Eur J Nucl Med Mol Imaging
the vertebrae and bone islands. Splenic and hepatic FDG up-
take was measured using VOIs at the center of the spleen and
center of the right liver lobe, excluding large vessels and le-
sions such as cysts and hemangiomas. The liver was used as a
reference organ for FDG uptake in the bone marrow and
spleen. Thus, bone marrow-to-liver SUV ratios (BLR) and
spleen-to-liver SUV ratios (SLR) were calculated. All SUVs
were corrected for plasma glucose levels according to the
European Association of Nuclear Medicine guidelines and
all scans were reconstructed according to resEARch 4 Life
[19].
Statistical analysis
For baseline data, all continuous variables were checked for
normal distribution using Kolmogorov-Smirnov tests. Data
were presented as mean ± standard deviation or median with
interquartile range (IQR) for normally distributed or non-
normally distributed data, respectively.
To investigate which factors were associated with bone
marrow and splenic FDG uptake, univariate linear regression
and multivariate (stepwise) linear regression analyses were
performed. BLR and SLR were selected as the dependent
variable. Age, gender, hemoglobin, leukocyte count, platelets,
glucose level, CRP, type of bacteria, days of antibiotic treat-
ment, infection focus, use of immunosuppressive drugs, dura-
tion of hospital stay (after FDG-PET/CT), ICU admission, and
mortality were used as independent variables. P values of <
0.05 were considered statistically significant.
All statistical analyses were performed using IBM
Statistical Package for the Social Sciences (SPSS) version
25 (SPSS, Chicago, IL).
Results
Patient population
Four hundred fifty-two FDG-PET/CT scans from 399
individual patients were potentially eligible for inclu-
sion. After review of the inclusion and exclusion
criteria, 145 FDG-PET/CT scans from 145 patients were
finally included (Fig. 1).
These included 90 men and 55 women, with a median age
of 64 years (IQR 22), median CRP level of 84 mg/L (IQR
100), and median leukocyte count of 10.0 × 109/L (IQR 6.6).
In all patients, bacteremia was most commonly caused by
Staphylococcus aureus (40 patients, 28% of total), Gram-
negative species (34 patients, 23% of total), and coagulase-
negative staphylococci (19 patients, 13% of total) (Table 1).
The most common foci of infection were musculoskeletal (31
patients, 21% of total), cardiovascular (28 patients, 19% of
total), and hepatopancreaticobiliary (20 patients, 14% of
total) (Table 2). Forty patients (28% of total) used immuno-
suppressive drugs at the time of the FDG-PET/CT, and 139
patients (96%) received antibiotic treatment before FDG-PET/
CT. The median total duration of hospital stay was 23 days
(IQR 27), and patients remained in the hospital for a median of
13 days (IQR 18) after FDG-PET/CT. Twenty-two patients
(15% of total) were admitted to the ICU during hospitaliza-
tion, and 19 patients (13% of total) died during hospital ad-
mission. The FDG-PET/CT images of two exemplary patients
are shown in Figs. 2 and 3.
Quantitative analysis FDG uptake
The median SUVmean of FDG in the bone marrow was 1.70
(IQR 0.81) among all included patients. The median SUVmean
in the spleen was 2.44 (IQR 0.99) and 2.29 (IQR 1.07) in the
right liver lobe. The median BLRwas 0.76 (IQR 0.40), and 38
patients (26%) showed increased FDG uptake in the bone
marrow (BLR > 1.00). The median SLR was 1.01 (IQR
0.31), with 75 patients (52%) showing increased FDG uptake
in the spleen (SLR > 1.00). In 32 patients (22%), both BLR
and SLR were elevated with ratios higher than 1.00 (Table 3).
Variables associatedwith increased bonemarrow FDG
uptake
On univariate linear regression, BLR was significantly asso-
ciated with 14 individual variables.
Duration of hospital stay after FDG-PET/CT, ICU
admission, bacteremia caused by Gram-negative or mul-
tiple bacteria, leukocyte count, CRP, platelets, detecting
any focus of infection on FDG-PET/CT, and having a
cardiovascular or musculoskeletal focus of infection
were positively associated with BLR. Age, duration of
antibiotic treatment before FDG-PET/CT, use of immu-
nosuppressive drugs, and glucose level were negatively
associated with BLR (Table 4). To identify which fac-
tors had the strongest independent association with high
bone marrow uptake, multivariate (stepwise) linear re-
gression analysis was performed.
For BLR, age showed the strongest independent associa-
tion (0.007 decrease in ratio per year increase), followed by
CRP (0.001 increase per unit increase in CRP), having a car-
diovascular (0.25 increase) or musculoskeletal (0.20 in-
crease) focus of infection, suffering from bacteremia
caused by Gram-negative bacteria (0.15 increase), and
glucose level before FDG-PET/CT (0.045 decrease in
ratio per mmol/L increase). Together, these variables
had an adjusted R2 of 0.46 (Table 5). No clinical out-
come variables were independently associated with
BLR.
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Variables associated with increased spleen FDG
uptake
On univariate linear regression, SLR was significantly associ-
ated with 11 individual variables. Bacteremia caused by
Gram-negative bacteria, Staphylococcus aureus, or multiple
bacteria, leukocyte count, CRP, detecting any focus of infec-
tion on FDG-PET/CT, and having a cardiovascular or muscu-
loskeletal focus of infection were positively associated with
SLR. Age, use of immunosuppressive drugs, and glucose lev-
el were negatively associated with BLR (Table 4). On multi-
variate (stepwise) linear regression, CRP showed the strongest
independent association with SLR (0.001 increase in ratio per
unit increase in CRP), followed by age (0.003 decrease in ratio
per year increase), glucose level before PET (0.039 decrease
per unit increase in glucose), and having a cardiovascular
focus of infection (0.12 increase). Together, these variables
had an adjusted R2 of 0.19. No clinical outcome variables
were independently associated with SLR (Table 6).
Discussion
Our study included 145 patients with confirmed bacteremia
who underwent FDG-PET/CT to find the focus of infection.
In 38 patients (26%), FDG uptake was increased in the bone
marrow (BLR > 1.00), and in 75 patients (52%), FDG uptake
was increased in the spleen (SLR > 1.00). In 32 patients
(22%), FDG uptake was increased in both the bone marrow
and spleen. With multivariate linear regression, age was the
strongest factor independently associated with BLR, followed
by CRP, having a cardiovascular of musculoskeletal focus of
infection, having bacteremia caused by Gram-negative bacte-
ria, and blood glucose level before FDG-PET/CT. For SLR,
CRP was the strongest independently associated factor,
followed by age, blood glucose level before FDG-PET/CT,
and having a cardiovascular focus of infection.
From a pathophysiological perspective, young age and
high CRP appear to be the most important explanatory factors
for a high BLR or SLR. It is known that bone marrow com-
position changes with aging. “Red bone marrow,” consisting
of 60% hematopoietic cells and 40% fat cells, gradually pro-
gresses with age to “yellow bone marrow” which consists of
95% fat cells and 5% nonfat cells [20]. Because hematopoietic
cells have a higher glucose metabolism than fat cells, more
FDG accumulates in the bone marrow of younger people un-
dergoing FDG-PET/CT, also when they are healthy. In pa-
tients with infectious disease, myelopoiesis and especially
granulopoiesis are stimulated more than in healthy patients,
leading to increased production of monocytes and
Fig. 1 After review of the
inclusion and exclusion criteria,
145 FDG-PET/CT scans from
145 patients were finally included
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granulocytes [21]. This process seems to amplify the effect of
young age on the bone marrow-to-liver ratio in patients with
bacteremia. Surprisingly, the hemoglobin level was not sig-
nificantly associated with BLR or SLR, while high FDG up-
take in the bone marrow or spleen has been associated with
anemia in patients with cancer [22–24]. Erythropoiesis is of-
ten suppressed during infection [25], which may be the reason
why a high BLR or SLR is not associated with hemoglobin
level in patients with bacteremia. However, the etiology of the
anemia should also be taken into account. For example, if
patients with bacteremia were already anemic due to chronic
disease, erythropoiesis may have already been suppressed be-
fore their episode of bacteremia [26].
Higher CRP levels were also independently associated
with a high BLR and SLR. This finding supports the hypoth-
esis that bone marrow and splenic FDG uptake are indeed
Table 1 Baseline characteristics
Characteristic Value
(n = 145)




Hemoglobin (mmol/L) 6.2 (1.5)a
C-reactive protein (mg/L) 84.0
(100)a
Leukocytes (× 109/L) 10.0 (6.6)a
Glucose level (mmol/L) 5.2 (1.5)a
Isolated bacteria from blood culture
Staphylococcus aureus 40 (28%)
Gram negatives 34 (23%)
Coagulase-negative staphylococci 19 (13%)
Enterococcus species 18 (12%)
Streptococcus species 15 (10%)
Other 2 (1%)
Polymicrobial 17 (12%)
Patients admitted to ICU 22 (15%)
Patients using immunosuppressive medication 40 (28%)
Patients receiving antibiotic treatment before FDG-PET/CT 139 (96%)
Days of antibiotic treatment before FDG-PET/CT 7 (9)a
Days between FDG-PET/CT and hospital discharge 13 (18)a
Total hospital stay (days) 23 (27)a









In-hospital mortality 19 (13%)
aMedian (interquartile range)
Table 2 Final diagnosis at hospital discharge




Septic arthritis 3 (2%)
Sternoclavicular infection 2 (1%)
Mediastinitis 1 (1%)
Psoas abscess 1 (1%)
Cardiovascular 28 (19%)
Endocarditis 15 (10%)
Vascular graft infection 7 (5%)
Septic thrombophlebitis 2 (2%)




Infected liver cyst 6 (4%)
Cholangitis 5 (3%)
Cholecystitis 3 (2%)
Liver abscess 3 (2%)
Necrotizing pancreatitis 2 (2%)
Surgical site infection after hemihepatectomy 1 (1%)
Gastrointestinal 9 (6%)
Esophagitis 2 (2%)
Mesenteric lymphadenitis 1 (1%)
Enterocolitis 1 (1%)
Diverticulitis 1 (1%)
Pseudomembranous colitis 1 (1%)
Sigmoiditis 1 (1%)
Ileum perforation 1 (1%)
Catheter/drain/other 8 (6%)
Infected intravenous catheter 5 (3%)
Infected venous access point 1 (1%)
Infected nephrostomy catheter 1 (1%)




Q fever 1 (1%)
Urogenital 7 (5%)
Pyelonephritis 3 (2%)
Infected kidney cyst 2 (2%)
Kidney abscess 2 (2%)
Unknown origin 34 (23%)
Eur J Nucl Med Mol Imaging
related to the severity of infection, or at least a heavier inflam-
matory response to infection. Having bacteremia caused by
Gram-negative bacteria also resulted in a higher BLR than
other microorganisms. This may be explained by previous
literature which states that bacteremia with Gram-negative
bacteria elicits a more severe immune response than Gram-
positive bacteria [27]. The spleen is especially involved in the
clearance of encapsulated bacteria [28]. These can be both
Gram-positive or Gram negative, which may be why bacter-
emia with Gram-negative bacteria did not cause a higher SLR
than bacteremia with other encapsulated bacteria, such as
Streptococcus pneumoniae or Staphylococcus aureus.
From a clinical perspective, it is an important finding that a
cardiovascular focus of infection was independently associat-
ed with a higher BLR and SLR. The most common cardio-
vascular infections in our study population were endocarditis,
vascular graft infection, septic thrombophlebitis, and mycotic
aneurysm. A possible explanation may be that these infections
may elicit a higher immune response than other infections.
With cardiovascular infections such as endocarditis and in-
fected vascular grafts, bacteria are constantly hematogenously
spread through the body. Eradication of the pathogen usually
requires up to 6 weeks of intravenous antibiotic therapy [29].
These infections are usually considered severe and as such
may also evoke a more severe inflammatory response
throughout the body, including the bone marrow and spleen.
Therefore, physicians should be especially attentive to a po-
tential cardiovascular focus of infection in case of a high BLR
or SLR. Additionally, a musculoskeletal infection was also
associated with a high BLR but not a high SLR. The reason
for this observation remains unclear. However, the majority of
musculoskeletal infections in this study consisted of
spondylodiscitis. Although infected vertebrae were excluded
from SUV measurements, it can be speculated that
spondylodiscitis may also cause higher FDG uptake in other
(adjacent) vertebral bone marrow due to the accumulation of
inflammatory cells. This requires further investigation.
Lastly, higher glucose levels before FDG-PET/CT were
also independently associated with a lower BLR and SLR.
The liver plays a key role in glucose regulation [30]. In pa-
tients with higher glucose levels, glycogenesis is stimulated,
causing more FDG to be phosphorylated to FDG-6-phosphate
and be “trapped” in the liver to lower blood glucose levels
[31]. This causes a higher increase in FDG uptake in the liver
Fig. 2 A 26-year-old man with no previous medical history presented at
the hospital with a fever of 39 °C and watery diarrhea after a holiday to
South America. A complete physical exam and a thoracic X-ray showed
no abnormalities. His leukocyte count was 3.8 × 109/L, and his CRP level
was 165 mg/L. Blood cultures were positive for Salmonella species.
Antibiotic treatment was initiated with ceftriaxone. Because his clinical
condition did not improve, FDG-PET/CT was performed to identify the
focus of infection. FDG-PET/CT showed diffuse high FDG uptake in the
bone marrow, including the spinal vertebrae (A, dashed white rectangle;
B, C, green circle) and pelvis (A, dashed white arrow) with a BLR of
1.40. FDG uptake in the spleen (A, C, white circle) was also higher than
in the liver (A, C, dashed white circle) with an SLR of 1.26. Apart from
mesenteric lymphadenitis (B, white arrow), no other infection focus was
found. Antibiotic therapy was continued, and the patient was discharged
1 week after FDG-PET/CT in good clinical condition
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than in the bone marrow and spleen and therefore lower bone
marrow-to-liver and spleen-to-liver ratios. Treatment with
corticosteroids can also increase glucose level and hepatic
FDG uptake [29], but BLR or SLR was not independently
associated with receiving immunosuppressive drugs (of which
85% were corticosteroids) in our patient population.
Previous literature about the relation between BLR, SLR,
and clinical or pathophysiological factors is very limited in
patients with infectious disease. In a study by Inoue et al.
[8], high BLR was also significantly associated with high
CRP and young age in 65 patients, but most of these patients
did not suffer from infectious disease. In a study by Ahn et al.
[16], FDG uptake in the spleen was higher in 38 patients with
macrophage activation syndrome than in 15 patients with sep-
sis. However, the patients with macrophage activation syn-
drome were significantly younger than the patients with sep-
sis, which may have influenced these results. In another study
by Ahn et al. [15], high BLR and SLR were correlated with
high CRP in 101 patients with localized infection, and BLR
and SLR were higher in 91 patients with the autoimmune
disease than in the patients with localized infection. Again,
the patients with autoimmune disease were significantly youn-
ger than the patients with localized infectious disease, which
Fig. 3 A 14-year-old boy presented to the hospital with an intermittent
fever up to 40 °C, fatigue, and painful muscles in his legs for approxi-
mately 2 weeks. His medical history included aortic valve replacement
with an artificial valve. On auscultation, a systolic murmur was heard,
which was loudest at the third intercostal space on the left side of the
sternum. His leukocyte count was 13.2 × 109/L, and his CRP level was
40 mg/L. Blood cultures were positive for Streptococcus parasanguinis.
A possible aortic valve vegetation was seen on a transthoracic ultrasound.
On FDG-PET/CT, pathologic FDG uptake of the aortic valve was seen
(A, B, white arrow), confirming the diagnosis of artificial valve endocar-
ditis. FDG uptake in the spleen (white circle) was evidently higher than in
the liver (dashed white circle), with an SLR of 1.73 and a BLR of 1.11.
Despite adequate antibiotic treatment, there was no clinical improvement,
and the aortic valve was surgically replaced 2 weeks after FDG-PET/CT.
Six weeks after the surgery, the patient could be discharged from the
hospital in good clinical condition







Right liver lobe SUVmean 2.29
(1.07)b
Bone marrow-to-liver ratio 0.76
(0.40)b
Patients with bone marrow-to-liver ratio > 1.00 38





Patients with spleen-to-liver ratio > 1.00 75
Range of spleen-to-liver ratio
Lowest 0.64
Highest 2.45
Patients with bone marrow-to-liver ratio and spleen-to-liver
ratio > 1.00
32
a Averaged SUVmean of the right humeral head, first thoracic vertebra,
first lumbar vertebra, and right posterior iliac crest
bMedian (interquartile range)
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Table 4 Univariate linear regression between bone marrow-to-liver ratio (BLR), spleen-to-liver ratio (SLR), and clinical (infection) parameters
Variable BLR SLR
Unstandardized B 95% CI Sig. Unstandardized B 95% CI Sig.
Age (years) − 0.007 − 0.010 to − 0.005 0.000 − 0.003 − 0.006 to − 0.001 0.002
Male gender − 0.015 − 0.12 to 0.093 0.786 0.004 − 0.087 to 0.095 0.93
Duration of stay after PET (days) 0.004 0.001 to 0.007 0.015 0.002 0.000 to 0.005 0.068
Days of antibiotic treatment − 0.008 − 0.015 to − 0.001 0.026 − 0.003 − 0.009 to 0.003 0.26
Using immunosuppressive drugs − 0.12 − 0.24 to − 0.008 0.036 − 0.125 − 0.22 to − 0.030 0.010
ICU admission 0.25 0.101 to 0.39 0.001 0.12 − 0.001 to 0.24 0.051
Mortality − 0.12 − 0.274 to 0.032 0.120 − 0.083 − 0.21 to 0.048 0.21
Microorganism
Coagulase negative Reference category Reference category
Enterococcus species − 0.021 − 0.22 to 0.18 0.83 0.062 − 0.11 to 0.23 0.48
Gram negatives 0.23 0.054 to 0.40 0.011 0.19 0.044 to 0.34 0.012
S. aureus 0.14 − 0.027 to 0.31 0.098 0.15 0.004 to 0.30 0.044
Streptococcus species 0.16 − 0.054 to 0.37 0.14 0.16 − 0.020 to 0.34 0.081
Polymicrobial 0.23 0.021 to 0.43 0.031 0.18 0.001 to 0.35 0.049
Other − 0.028 − 0.48 to 0.43 0.90 0.16 − 0.020 to 0.34 0.081
Laboratory values
Hemoglobin (mmol/L) − 0.007 − 0.052 to 0.038 0.75 − 0.005 − 0.043 to 0.033 0.80
Leukocyte count (× 109/L) 0.012 0.005 to 0.019 0.001 0.008 0.002 to 0.014 0.009
CRP (mg/L) 0.001 0.000 to 0.002 0.001 0.001 0.000 to 0.001 0.001
Platelets (× 109/L) 0.000 0.000 to 0.001 0.038 0.000 0.000 to 0.000 0.23
Glucose level (mmol/L) − 0.071 − 0.11 to − 0.032 0.001 − 0.051 − 0.085 to − 0.017 0.003
Detection of any focus 0.20 0.098 to 0.30 0.000 0.12 0.030 to 0.21 0.009
Focus of infection
Unknown origin Reference category Reference category
Gastrointestinal 0.13 − 0.083 to 0.35 0.23 0.066 − 0.12 to 0.26 0.49
Pulmonary 0.18 − 0.047 to 0.40 0.12 0.14 − 0.057 to 0.34 0.16
Cardiovascular 0.32 0.18 to 0.47 0.000 0.17 0.047 to 0.30 0.007
Musculoskeletal 0.25 0.11 to 0.39 0.001 0.14 0.022 to 0.27 0.021
Hepatopancreaticobiliary 0.13 − 0.031 to 0.29 0.11 − 0.026 − 0.17 to 0.11 0.71
Central line/catheter − 0.046 − 0.27 to 0.18 0.69 − 0.10 − 0.30 to 0.096 0.31
Table 5 Multivariate stepwise linear regression between bone marrow-to-liver ratio (BLR) and clinical (infection) parameters
Step in regression Variable Ra Adjusted R2a Unstandardized B (95% CI) β coefficient Sig.
1 Age (years) 0.47 0.22 − 0.007 (− 0.009 to − 0.005) − 0.446 0.000
2 CRP (mg/L) 0.55 0.30 0.001 (0.000–0.001) 0.18 0.006
3 Cardiovascular focus 0.61 0.36 0.25 (0.15 to 0.36) 0.34 0.000
4 Musculoskeletal focus 0.64 0.40 0.20 (0.09 to 0.305) 0.273 0.000
5 Gram-negative bacteria 0.67 0.43 0.15 (0.054 to 0.246) 0.195 0.002
6 Glucose before PET (mmol/L) 0.69 0.46 − 0.045 (− 0.076 to − 0.014) − 0.174 0.004
a In each subsequent step of the regression (steps 1 to 6), another variable is added to the model. The R and adjusted R2 show the cumulative effect of the
included variables at each step. In step 6, all variables from the table are included
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may have influenced the results, especially since age showed a
strong association with BLR and SLR in our study population.
In a recent study by Boursier et al. which included 129
patients with suspected endocarditis, high FDG uptake of
the bone marrow and spleen was independently associated
with “definitive” infective endocarditis [17]. Obesity and high
blood glucose levels resulted in a lower BLR or SLR and
having bacteremia resulted in a higher BLR or SLR.
Because bone marrow and spleen FDG uptake were grouped
together, the relation between the included variables and FDG
uptake of the bone marrow or spleen individually is unclear.
Also, 30% of the included patients did not have bacteremia,
which makes the results difficult to translate to all patients
with bacteremia.
In several types of cancer, increased FDG avidity of the
bone marrow seemed to be associated with prognostic factors
such as lower overall survival rate and higher cancer recur-
rence rate [9–14]. In our cohort of patients with bacteremia,
BLR or SLR was not associated with a total duration of hos-
pital stay, ICU admission, or mortality. There is no previous
literature about the relation between BLR or SLR and clinical
outcome in patients with infectious disease.
This study was compromised by some limitations. First,
due to its retrospective design, there may have been selection
bias. All included patients had bacteremia of unknown origin,
and they underwent FDG-PET/CT to locate the source of
infection. Patients with bacteremia who already have an
established focus of infection may not undergo FDG-PET/
CT. Therefore, it is uncertain whether the results of this study
also apply to patients with bacteremia of known origin.
Second, patients who were suspected of endocarditis were
instructed to limit carbohydrate intake for 24 h and fast for
6 h to suppress myocardial FDG uptake, but some patients still
had high glucose levels before FDG-PET/CT. Therefore, it
seems likely that some patients did not follow the dietary
instructions, which could have affected FDG-PET/CT results.
Lastly, the human inflammatory response to bacteremia is a
very complex process involving many different inflammatory
mediators. Although this study did include the most important
clinical factors (such as CRP and leukocytes), some specific
laboratory markers were not determined in most patients due
to the retrospective nature of this study and, therefore, not
analyzed. With multivariate linear regression, BLR reached
an adjusted R2 of 0.46, indicating that 46% of the variance
in BLR can be explained by age, CRP, focus of infection, type
of bacteria, and glucose level before FDG-PET/CT. For SLR,
age, CRP, focus of infection, and glucose before FDG-PET/
CT reached an adjusted R2 of 0.19. Because only 19% of SLR
could be explained by our included factors, it is likely that
other inflammatory markers (such as growth factors and cyto-
kines) also play an important explanatory role in FDG uptake
of the spleen in patients with bacteremia [32, 33]. It is known
that cytokines play a role in upregulation of active glucose
transporters (GLUT) in the plasma membrane of cells, which
also increases FDG uptake of these cells [34]. However, the
association between specific cytokines and FDG uptake in
bone marrow or the spleen is not described in the current
literature and cannot be explored by our study either due to
its retrospective nature. Future prospective studies should in-
clude additional variables such as specific cytokines, growth
factors, and progenitor cells involved in hematopoiesis to fur-
ther enhance our understanding of high FDG uptake in the
bone marrow and spleen of patients with bacteremia.
Conclusion
High FDG uptake in the bone marrow is associated with a
higher inflammatory response and younger age in patients
with bacteremia. In patients with high FDG uptake in the bone
marrow, a cardiovascular or musculoskeletal focus of infec-
tion is more likely than other foci, and the infection is more
often caused by Gram-negative species. High splenic FDG
uptake is associated with a higher inflammatory response as
well, and a cardiovascular focus of infection is also more
likely in case of high splenic FDG uptake.
Availability of data and material Due to patient confidential-
ity, the database will not be made available online. The corre-
sponding author can be contacted to discuss possibilities on
sharing data included in this study.
Table 6 Multiple stepwise linear regression between spleen-to-liver ratio (SLR) and (clinical) infection parameters
Step in regression Variable Ra Adjusted R2a Unstandardized B (95% CI) β coefficient Sig.
1 CRP (g/L) 0.27 0.065 0.001 (0.000 to 0.001) 0.249 0.001
2 Age (years) 0.38 0.13 − 0.003 (− 0.005 to − 0.001) − 0.239 0.002
3 Glucose before PET (mmol/L) 0.42 0.16 − 0.039 (− 0.071 to − 0.007) − 0.186 0.016
4 Cardiovascular focus 0.46 0.19 0.12 (0.019 to 0.22) 0.177 0.020
a In each subsequent step of the regression (steps 1 to 4), another variable is added to the model. The R and adjusted R2 show the cumulative effect of the
included variables at each step. In step 4, all variables from the table are included
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